First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers

BACKGROUND: YS110 is a humanised IgG1 monoclonal antibody with high affinity to the CD26 antigen. YS110 demonstrated preclinical anti-tumour effects without significant side effects. METHODS: This FIH study was designed to determine the maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D...

Descripción completa

Detalles Bibliográficos
Autores principales: Angevin, Eric, Isambert, Nicolas, Trillet-Lenoir, Véronique, You, Benoit, Alexandre, Jérôme, Zalcman, Gérard, Vielh, Philippe, Farace, Françoise, Valleix, Fanny, Podoll, Thomas, Kuramochi, Yu, Miyashita, Itaru, Hosono, Osamu, Dang, Nam H, Ohnuma, Kei, Yamada, Taketo, Kaneko, Yutaro, Morimoto, Chikao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418443/
https://www.ncbi.nlm.nih.gov/pubmed/28291776
http://dx.doi.org/10.1038/bjc.2017.62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418443/
https://www.ncbi.nlm.nih.gov/pubmed/28291776
http://dx.doi.org/10.1038/bjc.2017.62

Ejemplares similares